ClinicalTrials.gg
WithdrawnNCT04490486COVID-19Updated May 12, 2022

Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19

A Phase 1 interventional study of UCMSCs and Placebo in COVID-19, Acute Respiratory Distress Syndrome and Corona Virus Infection, sponsored by Joshua M Hare. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-12.

Sponsored by Joshua M Hare · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Not Funded

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate the safety of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UCMSCs) administered intravenously in patients with acute pulmonary inflammation due to COVID-19 with moderately severe symptoms

02

Conditions studied

  • COVID-19
  • Acute Respiratory Distress Syndrome
  • Corona Virus Infection

Keywords

  • Acute Pulmonary Inflammation
03

In context

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Joshua M Hare is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written
  2. Male or female subjects age > 18 years at the time of signing the Informed Consent Form.
  3. COVID-19 positive according to diagnosis (evaluated by reverse transcription (RT)-polymerase chain reaction (PCR) test confirming infection with severe acute respiratory syndrome coronavirus and clinical management of COVID-19 criteria (refer to appendix B)
  4. Individuals with moderate to severe COVID-19 symptoms.

    • Moderate:
    • Patients with moderate disease are symptomatic (e.g. fever, cough, headache, myalgia, sore throat, nasal congestion, nausea, vomiting, diarrhea, fatigue, anosmia, or dysgeusia) and have abnormal chest imaging or some degree of hypoxia requiring supplemental oxygen but not intubation.
    • Moderate-severe:
    • The Moderately Severe disease category includes patients who are symptomatic (as described above), have abnormal chest imaging, but also have worsening hypoxia compatible with mild acute respiratory distress syndrome (ARDS) (Partial Pressure of Oxygen (PaO2)/Fraction of Inspired Oxygen (FiO2) \</= 300 but > 200) - Berlin criteria; but do not yet require intubation .
  5. Adequate venous access
  6. For female patients only, willingness to use FDA-recommended until 6 months post treatment.
  7. Must agree to comply with all study requirements and be willing to complete all study visits.
  8. Need in-patient admission

Exclusion criteria

Exclusion Criteria:

  1. PaO2/FiO2 \</= 200
  2. Anticipated intubation within 24h
  3. Be a female who is pregnant, nursing, or of while not practicing effective methods. Female subjects must undergo a blood pregnancy test at screening and prior to infusion.
  4. Inability to perform any of the assessments required for endpoint analysis.
  5. Subjects that are unsuitable with the study requirements .
  6. Active listing (or expected future listing) for transplant of any organ.
  7. Have known allergies to penicillin or streptomycin.
  8. Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.
  9. Have a history of organ or cell transplant rejection
  10. Has a history of an adverse response to cell-based therapy
  11. Have presence of any active (other than non-melanoma skin cancer) that required treatment within the last 1 year.
  12. History of active drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months
  13. Be serum positive for , Surface antigen of virus (HBsAg) or Viremic .
  14. Severe hepatic impairment (defined as liver cirrhosis Child stage B or C);
  15. Stage 4 chronic kidney disease or currently receiving chronic dialysis;
  16. Advanced cardiac (eg, severe heart failure [ (NYHA) III-IV]) or pulmonary diseases;
  17. Has uncontrolled hypertension as defined by BP systolic above 180 and diastolic above 110 which, in the Investigator's judgment, would not make participation appropriate;
  18. Known allergy or to stem cell infusions or its components;
  19. Current enrollment in an drug or participation in such a study within 15 days of entry into this study;
  20. Moderate to severe liver failure (Childs-Pugh Score > 10) (ALT)/Aspartate Aminotransferase (AST) > 5 times the ;
  21. Congenital prolonged syndrome;
  22. Current QT corrected (QTc) above 490 msec. If patient has Q, R and S waves (QRS) interval greater or equal to 120 msec, then the QT/QTc will be normalized to a QRS interval of 110 msec. (For instance, if the patient has a bundle branch block with QRS of 140 msec and QT/QTc of 470 msec, the normalized QTc will be 470;
  23. Subjects taking drugs that could affect the QT interval (e.g. procainamide, disopyramide, mexiletine, flecainide, propafenone, amiodarone, sotalol, cimetidine, dronedarone, dofetilide, levofloxacin, ciprofloxacin, moxifloxacin);
  24. Anticipated transfer to another hospital which is not a study site within 72 hours;
  25. Coagulopathy ( less than 80,000, or (PT)/Partial Thromboplastin time (PTT) twice normal range without systemic anticoagulation;
  26. Greater than 24h since first meeting ARDS criteria (Berlin definition) or 72h of ICU admission;
  27. Subjects who are legally detained in an official institution;
  28. A previous MSC infusion in last 30 days not related to this trial;
  29. History of Pulmonary Hypertension (WHO Class III/IV);
  30. Unstable arrhythmia or uncontrolled hypertension not responding to best ICU treatment;
  31. Patients currently receiving Extracorporeal Membrane Oxygenation (ECMO);
  32. Any other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%;
  33. Moribund patient not expected to survive > 24 hours;
  34. The investigator believes that participating in the trial is not in the best interest of the patient, or the investigator considers patient unsuitable for enrollment (such as unpredictable risks or subject compliance issues)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1: (UCMSCs)

    Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.

    Biological: UCMSCs

  • Placebo comparator
    Group 2: (Placebo)

    Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3.

    Other: Placebo

Interventions

  • BiologicalUCMSCs

    100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.

  • OtherPlacebo

    Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion

06

What researchers measure

Primary outcomes

  1. Percent of participants with treatment related Serious Adverse Events (SAE)

    Safety of UCMSCs will be reported as the percentage of participants in each treatment group that experienced a treatment related SAEs.

    Time frame: 12 months

Secondary outcomes

  1. Change in inflammatory marker levels

    Change in serum inflammatory marker levels including Interleukin (IL) IL-6, IL-2, Tumor Necrosis Factor Alpha (TNF-a) and procalcitonin will be evaluated in ng/L.

    Time frame: Baseline, Day 30

  2. Change in systemic inflammatory marker levels

    Change in serum systemic inflammatory marker levels including D-dimer, high sensitivity C-reactive protein (hsCRP) and ferritin will be evaluated in mg/L.

    Time frame: Baseline, Day 30

  3. COVID-19 Viral Load

    Assessed using blood samples or nose/throat swabs.

    Time frame: Up to 30 Days

  4. Change in SOFA score

    Sequential Organ Failure Assessment (SOFA) will be used to assess organ failure including the cardiovascular system, coagulation system, liver, kidney and other extra-pulmonary organs. SOFA score ranges from 0-24 with the higher score indicating worse outcomes.

    Time frame: Baseline, Up to 30 Days

  5. Change in electrolytes levels

    Sodium, Potassium, Chloride and Carbon Dioxide (CO2) will be evaluated in mmol/L. Changes from baseline to Day 30 will be compared between groups.

    Time frame: Baseline, Up to 30 Days

  6. Change in LDH levels

    Serum Lactate Dehydrogenase (LDH) levels assessed in U/L. Changes in LDH from baseline to Day 30 will be compared between groups.

    Time frame: Baseline, Up to 30 Days

  7. Number of subjects discharged from the ICU

    ICU monitoring status will be reported as the number of subjects discharged from the ICU within 7 days.

    Time frame: Up to 7 Days

  8. Percentage of participants with less requirement for vasoactive agents

    Percentage of participants requiring less use of vasoactive agents will be reported.

    Time frame: Up to 30 Days

  9. Rate of Mortality

    Percentage of participant deaths throughout the study period.

    Time frame: Up to 30 Days

  10. Percentage of participants with changes in immune marker expression

    The percentage of participants with changes in serum immune marker levels including Cluster of Differentiation (CD) CD 4+ and CD 8+, as evaluated by treating physician will be reported.

    Time frame: Up to 30 Days

  11. Percentage of participants with changes in radiologic findings

    Percentage of participants with changes in their chest imaging such as ground-glass opacity, local patch shadowing, bilateral patch shadowing and interstitial abnormalities will be reported. Imaging will be assessed by treating physician using chest radiography or chest Computed Tomography (CT).

    Time frame: Up to 30 Days

  12. Percentage of participants with less pneumonia symptoms

    Percentage of participants showing less pneumonia symptoms will be reported as evaluated by treating physician using chest radiography or chest CT.

    Time frame: Up to 30 Days

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2022; primary completion for Jun 2024, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2020
First posted
Jul 29, 2020
StartEst.
Oct 1, 2022
Primary completionEst.
Jun 1, 2024
CompletionEst.
Jun 1, 2024
Last update
May 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04490486
Lead sponsor
Joshua M Hare
Responsible party
Joshua M Hare (Director of ISCI, Louis Lemberg Professor of Medicine, University of Miami) — Sponsor-investigator
First posted
Jul 29, 2020
Start date
Oct 1, 2022 (estimated)
Primary completion
Jun 1, 2024 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
May 12, 2022

Study contacts

Joshua M Hare, MD
principal investigator · ISCI/University of Miami Miller School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion